Litifilimab Trial Showed Efficacy for Lupus Patients
The monoclonal antibody improved skin symptoms in patients with cutaneous lupus erythematosus.
Updated on Oct. 2, 2026 in Arthritis
Live Poll
Do you feel that new medical treatments are generally making chronic disease management more effective?
The AMETHYST Part A trial demonstrated sustained efficacy for litifilimab in patients with active cutaneous lupus erythematosus. Participants showed consistent improvements in erythema scores through 52 weeks of treatment.
Why it matters
Litifilimab targets blood dendritic cell antigen 2 to reduce type I interferon and proinflammatory cytokines in lupus patients. This therapy offers a potential alternative for individuals who do not respond adequately to current antimalarial standard treatments.
The study included 93 participants, with 59 receiving litifilimab and 34 receiving placebo. By week 52, 27.2% of early-start participants achieved CLA-IGA-R erythema scores of 0-1, while 28.8% reached a CLASI-70 response.
The players
AMETHYST Part A
This is a phase 2/3 operationally seamless clinical study evaluating the efficacy and safety of litifilimab.
The details
Participants received subcutaneous injections every four weeks throughout the trial. Those initially assigned to the placebo group who switched to litifilimab at week 24 showed a clinical response within approximately four weeks.
Timeline
The primary endpoint assessment for erythema scores occurred at Week 16.
Placebo participants transitioned to open-label treatment at Week 24.
The study concluded data collection at Week 52.
Trial results were presented at the EADV 2026 Congress in Vienna from September 30-October 3, 2026.
The Big Picture
This study follows the methodology established by the 2022 LILAC Part B trial to refine therapeutic options for lupus. It extends those findings by providing critical long-term data on the efficacy of the monoclonal antibody litifilimab in a persistent patient population.
Patients currently struggling with limited response to standard antimalarial therapies may find new hope in this monoclonal antibody treatment. The trial demonstrates that even late-start patients can achieve clinical improvements within four weeks of beginning the medication.
The takeaway
Litifilimab represents a targeted approach to managing cutaneous lupus by neutralizing specific cytokines that drive skin inflammation. Patients should consult with their rheumatologist to discuss how emerging monoclonal antibody therapies fit into their current long-term treatment plan.
Further reading
Learn more about the latest research in this field on our Arthritis page.
Live Poll
Do you feel that new medical treatments are generally making chronic disease management more effective?
